Legal Representation
Attorney
Jeffrey Klembczyk
USPTO Deadlines
Next Renewal Deadline
1855 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2024-08-06)
Due Date
August 06, 2030
Grace Period Ends
February 06, 2031
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 eventsDate | Code | Type | Description |
---|---|---|---|
Apr 9, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
Apr 9, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
Apr 9, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
Apr 9, 2025 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS |
Aug 6, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
Aug 6, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
May 21, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
May 21, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
May 1, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
Apr 16, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
Apr 12, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Apr 12, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Apr 12, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Apr 11, 2024 | GNRT | F | NON-FINAL ACTION E-MAILED |
Apr 11, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
Apr 11, 2024 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Apr 8, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
Feb 26, 2024 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Feb 26, 2024 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceutical products, namely, injection solutions for human use in the treatment of cardiovascular disease; preparations for human health care in the treatment of cardiovascular disease; cardiovascular pharmaceutical preparations; local anesthetics for human use; inhalant anesthetic; pharmaceutical preparations for the induction of local anesthesia; general anesthetics for human use; transdermal patches featuring scopolamine for treatment of nausea and vomiting; antibiotics for human use; sedatives for human use; injectable pharmaceuticals for treatment of infections, bacterial infections, viral infections, pain, fever, hypertension, low blood pressure, heart disease, chest pain, hemodynamic imbalances, blood clots, ulcers, ventricular fibrillation, yeast infections, fungal infections, heart failure, diabetes, cancer, nausea and vomiting, edema, constipation, cirrhosis, opioid overdose, poisoning, heavy bleeding, dehydration, swelling, low magnesium, acne, rapid heartbeats, and low calcium; prescription medicines, namely, pills, tablets, capsules and pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of nausea, vomiting, and damage to bladder; pharmaceutical preparations to temporarily arrest the heart; pharmaceutical preparations for use in cardiac rhythm support; potassium preparations for pharmaceutical purposes; insulin; pharmaceutical preparations, namely, irrigation solutions for flushing, rinsing and cleansing of body tissues, body cavities, and wounds; medical instruments, namely, medical containers and medical bags sold filled with medical liquids and solutions, namely, irrigation solutions for cleansing wounds; amino acid preparations for medical purposes; liquid nutritional supplement; liquid vitamin supplements; saline solution for medical purposes; sterile water for medical purposes
First Use Anywhere:
Jan 1, 2023
First Use in Commerce:
Jan 1, 2023
Classification
International Classes
005